SIM0603

SIM0603 is an investigational small molecule drug candidate developed by Simcere Pharmaceutical (specifically through its subsidiary Jiangsu Xiansheng Re Ming Pharmaceutical) for the treatment of neurological disorders, primarily Alzheimer's disease. The compound is designed to target the amyloid-beta (Aβ) pathway, which is a central component of the amyloid hypothesis of Alzheimer's pathogenesis. SIM0603 functions as an inhibitor of Aβ aggregation, aiming to prevent the formation of neurotoxic oligomers and amyloid plaques that contribute to neurodegeneration and cognitive decline. The drug is intended to be a disease-modifying therapy, particularly for patients in the early stages of the disease. As of 2024, SIM0603 has entered clinical development, with Phase 1 trials underway to evaluate its safety, tolerability, and pharmacokinetics.

Other names

AGPh